Previously we described induction of cross-reactive HIV-1 neutralizing antibody responses in rabbits using a soluble HIV-1 gp140 envelope glycoprotein (Env) in an adjuvant containing monophosphoryl lipid A (MPL) and QS21 (AS02A). Here, we compared different forms of the same HIV-1 strain R2 Env for antigenic and biophysical characteristics, and in rabbits characterized the extent of B cell induction for specific antibody expression and secretion and neutralizing responses. The forms of this Env that were produced in and purified from stably transformed 293T cells included a primarily dimeric gp140, a trimeric gp140 appended to a GCN4 trimerization domain (gp140-GCN4), gp140-GCN4 with a 15 amino acid flexible linker between the gp120 and gp4...
HIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR-FL and ...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
AbstractHIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR...
Previously we described induction of cross-reactive HIV-1 neutralizing antibody responses in rabbits...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
BACKGROUND: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
AbstractThe human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex,...
Trimeric soluble forms of HIV gp140 envelope glycoproteins represent one of the closest molecular st...
Evaluating the structure-function relationship of viral envelope (Env) evolution and the development...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
AbstractThe elicitation of broadly neutralizing antibodies directed against the human immunodeficien...
AbstractImproving the potency, breadth, and durability of neutralizing antibody responses to HIV are...
UnlabelledEliciting broadly reactive functional antibodies remains a challenge in human immunodefici...
HIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR-FL and ...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
AbstractHIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR...
Previously we described induction of cross-reactive HIV-1 neutralizing antibody responses in rabbits...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
BACKGROUND: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
AbstractThe human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex,...
Trimeric soluble forms of HIV gp140 envelope glycoproteins represent one of the closest molecular st...
Evaluating the structure-function relationship of viral envelope (Env) evolution and the development...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
AbstractThe elicitation of broadly neutralizing antibodies directed against the human immunodeficien...
AbstractImproving the potency, breadth, and durability of neutralizing antibody responses to HIV are...
UnlabelledEliciting broadly reactive functional antibodies remains a challenge in human immunodefici...
HIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR-FL and ...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
AbstractHIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR...